H. Connors

Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.

W. Chung, K. Clément, I. Farooqi, 2020, The lancet. Diabetes & endocrinology.

Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency

K. Clément, S. O’Rahilly, R. Cone, 2017, Molecular metabolism.